Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_assertion description "[Sofosbuvir (SOF), a NS5B nucleotide polymerase inhibitor with pan-genotypic activity and a high-barrier to resistance, has been approved by FDA and EMA in an all oral combination therapy for chronic hepatitis C with ribavirin (RBV) alone, or in combination with either pegylated interferon/RBV or other DAAs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_assertion evidence source_evidence_literature NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_assertion SIO_000772 25645644 NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_assertion wasDerivedFrom befree-2016 NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_assertion wasGeneratedBy ECO_0000203 NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.
- befree-2016 importedOn "2016-02-19" NP1260439.RAsGfIicD0bgfJD8F7o48Kd5eGgu44Bfc4ADLpPCmm9rw130_provenance.